HBI-2375 / HUYA Bioscience - LARVOL DELTA

HBI-2375, a first-in-class IND ready selective MLL1-WDR5 inhibitor, retains desirable preclinical characteristics in solid tumors and in leukemias to be pursued in clinical studies (AACR 2024) - "Tissue distribution studies also showed greater accumulation of HBI-2375 in brain tissue indicative of a potential to target glioma and glioblastoma in clinical studies. Therefore, HBI-2375 represents a first-in-class MLL1-WDR5 inhibitor with promising characteristics for future testing in the clinic."

IO biomarker • Preclinical • Brain Cancer • CNS Tumor • Colorectal Cancer • Gastrointestinal Cancer • Glioblastoma • Glioma • Hematological Malignancies • Leukemia • Lung Cancer • Oncology • Solid Tumor • CD8 • WDR5

HBI-2375, a selective inhibitor of MLL1-WDR5 interaction, possesses desirable preclinical characteristics in solid tumors in combination with checkpoint inhibitors and also in leukemias in the future clinical investigations. (AACR-NCI-EORTC 2023) - No abstract available

Checkpoint inhibition • Combination therapy • Preclinical • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • WDR5